Page 5 - Regulating Stem Cells News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Hemostemix Inc.: Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list Hemostemix" or the " Company") is pleased to announce the completion of the Phase II Clinical Trial subject follow up, as the 65 th (final) subject has completed their last follow-up visit. With subject follow up now completed the Company is shifting its focus to completing the data analyses and reporting associated with finalizing their Phase II Clinical Trial. In addition, the Company has contracted two additional clinical research associates to assist with the completion of the s...

TORONTO, ON and NEW YORK, NY / ACCESSWIRE / March 16, 2021 / GlobeX Data Ltd. (OTCQB:SWISF) (CSE:SWIS) (FRA:GDT) ("GlobeX" or the "Company"), the leader in Swiss hosted secure communications and secure

Hemostemix Inc.: Hemostemix Announces HS 12 - 01 Clinical Trial Completion of Subjects' Follow-Up Visits at the End of March and Warrants Extended and Repriced Hemostemix" or the " Company") is pleased to announce that all follow-up visits of the subjects enrolled in the HS 12 -01 clinical trial will be completed by March 31, 2021. A total 65 subjects who were enrolled in the trial, randomized 2:1 to receive ACP-01 or a placebo, will have completed the last follow-up appointments by March 31, 2021. The Company will provide additional information once trial data has been analyzed. Warrant Amen...

Hemostemix Inc.: Hemostemix Announces Private Placement Update Hemostemix" or the " Company") announces that it was granted price protection of its previously announced non-brokered private placement of units (" Units") announced on December 18, 2020, for gross proceeds of up to $2,750,000 (the " Offering"). The Offering will consist of the issuance of an aggregate of up to 9,166,666 post rollback Units at a price of $0.30 per Unit. Each Unit consists of one post rollback common share in the capital of the Company (" Common Share") and one post rollback common share purchase warrant (" Warr...

Calgary, Alberta--(Newsfile Corp. - December 23, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") The Company is pleased to announce that the previously disclosed proposed